RxDoctor Payments Data

Lorraine McRae, MD

Family Medicine · Savannah, GANPI 1912928912

Payments from drug & device makers

$10,193in general payments, 2019–2025

Across 648 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Pfizer$855
  • AstraZeneca$842
  • Lilly USA, LLC$746
  • Amgen$689
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$10,02198%
  • Education$1722%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,193 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$40,620
Medicare patients
200
Services billed
676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide154$199,001
JardianceEmpagliflozin96$109,827
MounjaroTirzepatide50$65,833
FarxigaDapagliflozin Propanediol51$63,549
EliquisApixaban53$56,350
TrulicityDulaglutide51$50,789
Repatha SureclickEvolocumab43$28,295
Janumet XrSitagliptin Phos/Metformin Hcl39$26,520
JanuviaSitagliptin Phosphate16$26,431
Tresiba Flextouch U-200Insulin Degludec24$24,129
RexultiBrexpiprazole15$20,168
LinzessLinaclotide15$18,687
Tresiba Flextouch U-100Insulin Degludec30$17,986
Xigduo XrDapaglifloz Propaned/Metformin12$16,542
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,295$199,001154 claims
Lilly USA, LLCMounjaro, Trulicity$746$116,622101 claims
Boehringer IngelheimJardiance, Spiriva Respimat$236$116,075108 claims
AstraZenecaFarxiga, Symbicort$842$68,52264 claims
PfizerEliquis$855$56,35053 claims
MerckJanumet Xr, Januvia$87$52,95155 claims
AbbVieLinzess, Synthroid$1,175$22,98571 claims
Otsuka America Pharmaceutical, Inc.Rexulti$283$20,16815 claims
GSKTrelegy Ellipta, Incruse Ellipta$250$19,20635 claims
Johnson & JohnsonXarelto$223$13,86211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →